AU2003271681A8 - Monoclonal antibody anti-c3-2 directed against the third component of complement (c3) and its use in methods to inhibit complement activation - Google Patents

Monoclonal antibody anti-c3-2 directed against the third component of complement (c3) and its use in methods to inhibit complement activation

Info

Publication number
AU2003271681A8
AU2003271681A8 AU2003271681A AU2003271681A AU2003271681A8 AU 2003271681 A8 AU2003271681 A8 AU 2003271681A8 AU 2003271681 A AU2003271681 A AU 2003271681A AU 2003271681 A AU2003271681 A AU 2003271681A AU 2003271681 A8 AU2003271681 A8 AU 2003271681A8
Authority
AU
Australia
Prior art keywords
complement
methods
component
monoclonal antibody
directed against
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2003271681A
Other versions
AU2003271681A1 (en
Inventor
Hilde De Winter
Marie-Ange Buysse
Erik Hack
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
SANQUIN BLOOD SUPPLY FOUNDATIO
Stichting Sanquin Bloedvoorziening
Original Assignee
SANQUIN BLOOD SUPPLY FOUNDATIO
Stichting Sanquin Bloedvoorziening
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by SANQUIN BLOOD SUPPLY FOUNDATIO, Stichting Sanquin Bloedvoorziening filed Critical SANQUIN BLOOD SUPPLY FOUNDATIO
Publication of AU2003271681A1 publication Critical patent/AU2003271681A1/en
Publication of AU2003271681A8 publication Critical patent/AU2003271681A8/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
AU2003271681A 2002-10-04 2003-10-03 Monoclonal antibody anti-c3-2 directed against the third component of complement (c3) and its use in methods to inhibit complement activation Abandoned AU2003271681A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP02447190 2002-10-04
EP02447190.6 2002-10-04
US41894702P 2002-10-16 2002-10-16
US60/418,947 2002-10-16
PCT/EP2003/010989 WO2004031240A1 (en) 2002-10-04 2003-10-03 Monoclonal antibody anti-c3-2 directed against the third component of complement (c3) and its use in methods to inhibit complement activation

Publications (2)

Publication Number Publication Date
AU2003271681A1 AU2003271681A1 (en) 2004-04-23
AU2003271681A8 true AU2003271681A8 (en) 2004-04-23

Family

ID=32071097

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2003271681A Abandoned AU2003271681A1 (en) 2002-10-04 2003-10-03 Monoclonal antibody anti-c3-2 directed against the third component of complement (c3) and its use in methods to inhibit complement activation

Country Status (2)

Country Link
AU (1) AU2003271681A1 (en)
WO (1) WO2004031240A1 (en)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7999082B2 (en) 2004-02-10 2011-08-16 National Jewish Medical And Research Center Anti-factor B antibodies
CN101227924A (en) * 2005-05-26 2008-07-23 科罗拉多大学评议会 Inhibition of the alternative complement pathway for treatment of traumatic brain injury, spinal cord injury and related conditions
CN101668773B (en) 2007-03-14 2016-08-31 亚力史制药公司 humaneered anti-factor B antibody
RS20120461A1 (en) 2009-07-02 2013-06-28 Musc Foundation For Research Development Methods of stimulating liver regeneration
EP2855529A4 (en) 2012-05-24 2015-12-09 Alexion Pharma Inc Humaneered anti-factor b antibody
CA3093356A1 (en) 2018-04-03 2019-10-10 Ngm Biopharmaceuticals, Inc. C3-binding agents and methods of use thereof
WO2022171771A1 (en) * 2021-02-12 2022-08-18 Boehringer Ingelheim International Gmbh Complement c3 antigen binding proteins
WO2024086555A1 (en) 2022-10-17 2024-04-25 Ngm Biopharmaceuticals, Inc. Uses of anti-c3 antibodies

Also Published As

Publication number Publication date
WO2004031240A1 (en) 2004-04-15
AU2003271681A1 (en) 2004-04-23

Similar Documents

Publication Publication Date Title
EP1787998A4 (en) Antibody and utilization of the same
IL168058A0 (en) Antibodies that bind celi-associated ca 125/0722p and methods of use thereof
EP1572900A4 (en) Antibodies directed to pdgfd and uses thereof
IL164181A0 (en) Anti-il-tif antibodies and methods of using in inflammation
EP1609803A4 (en) Modified antibody against cd22 and utilization thereof
IL190502A0 (en) Anti-addl monoclonal antibody and use thereof
IL164021A0 (en) Antibodies and anti-pharmaceutical compositions containing the same
IL179476A0 (en) Antibodies against human interleukin-13 and uses therefor
IL164400A0 (en) Deruvatuves if n-Äphenyl(piperidin-2-yl)methylÜbenzamide, the preparation method thereof and application of same in therapeutics
HK1099935A1 (en) Anti-cd3 antibodies and methods of use thereof -cd3
IL176755A0 (en) M-csf-specific monoclonal antibody and uses thereof
HK1091132A1 (en) Anti-cd33 antibodies and the use thereof -cd33
AP2007003890A0 (en) Antibodies directed against amy-loid-beta peptide and methods using same
IL175586A0 (en) Interferon alpha antibodies and their uses
LT2368907T (en) Anti-Abeta antibodies and their use
EP1817055A4 (en) Ovr110 antibody compositions and methods of use
EP1492870A4 (en) Antibodies that bind to integrin alpha-v-beta-6 and methods of use thereof
EP1699485A4 (en) Anti-hydroxylase antibodies and uses thereof
AU2003271681A8 (en) Monoclonal antibody anti-c3-2 directed against the third component of complement (c3) and its use in methods to inhibit complement activation
AU2003227148A8 (en) Anti-ck18 monoclonal antibody and therapeutic and diagnostic uses thereof in cancer
IL173754A (en) Magnesium complex for the enhancement of magnesium uptake in mammals and use thereof
AU2003274963A8 (en) Mda-7 and free radicals in the treatment of cancer
PL374439A1 (en) Antibodies and uses thereof
AU2003249533A8 (en) Neoplasm specific antibodies and uses thereof
EP1813671A4 (en) Soluble protein and utilization of the same

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase